These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line. Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244 [TBL] [Abstract][Full Text] [Related]
23. Locating the unpaired cysteine of tissue-type plasminogen activator. Sehl LC; Nguyen HV; Berleau LT; Arcila P; Bennett WF; Keyt BA Protein Eng; 1996 Mar; 9(3):283-90. PubMed ID: 8736495 [TBL] [Abstract][Full Text] [Related]
24. Stimulation by fibrinogen of the amidolytic activity of single-chain tissue plasminogen activator. Urano T; deSerrano VS; Urano S; Castellino FJ Arch Biochem Biophys; 1989 Apr; 270(1):356-62. PubMed ID: 2494944 [TBL] [Abstract][Full Text] [Related]
25. Identification of a hydrophobic exosite on tissue type plasminogen activator that modulates specificity for plasminogen. Ke SH; Tachias K; Lamba D; Bode W; Madison EL J Biol Chem; 1997 Jan; 272(3):1811-6. PubMed ID: 8999865 [TBL] [Abstract][Full Text] [Related]
26. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains. Collen D; Lijnen HR; Bulens F; Vandamme AM; Tulinsky A; Nelles L J Biol Chem; 1990 Jul; 265(21):12184-91. PubMed ID: 2115513 [TBL] [Abstract][Full Text] [Related]
27. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain. Ikenaka Y; Yajima K; Yahara H; Maruyama H; Matsumoto K; Okada K; Ueshima S; Matsuo O Blood Coagul Fibrinolysis; 1992 Aug; 3(4):381-7. PubMed ID: 1330023 [TBL] [Abstract][Full Text] [Related]
28. The sequence A alpha-(154-159) of fibrinogen is capable of accelerating the t-PA catalysed activation of plasminogen. Schielen WJ; Adams HP; Voskuilen M; Tesser GI; Nieuwenhuizen W Blood Coagul Fibrinolysis; 1991 Jun; 2(3):465-70. PubMed ID: 1932532 [TBL] [Abstract][Full Text] [Related]
29. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site. Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727 [TBL] [Abstract][Full Text] [Related]
30. The influence of fibrin(ogen) fragments on the kinetic parameters of the tissue-type plasminogen-activator-mediated activation of different forms of plasminogen. Nieuwenhuizen W; Voskuilen M; Vermond A; Hoegee-de Nobel B; Traas DW Eur J Biochem; 1988 May; 174(1):163-9. PubMed ID: 3131143 [TBL] [Abstract][Full Text] [Related]
31. Initial interaction between fibrin and tissue plasminogen activator (t-PA). The Gly-Pro-Arg-Pro binding site on fibrin(ogen) is important for t-PA activity. Kaczmarek E; Lee MH; McDonagh J J Biol Chem; 1993 Feb; 268(4):2474-9. PubMed ID: 8428923 [TBL] [Abstract][Full Text] [Related]
32. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow. Graham DA; Huang TC; Keyt BA; Alevriadou BR Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163 [TBL] [Abstract][Full Text] [Related]
33. Effects of N-glycosylation on in vitro activity of Bowes melanoma and human colon fibroblast derived tissue plasminogen activator. Wittwer AJ; Howard SC; Carr LS; Harakas NK; Feder J; Parekh RB; Rudd PM; Dwek RA; Rademacher TW Biochemistry; 1989 Sep; 28(19):7662-9. PubMed ID: 2514792 [TBL] [Abstract][Full Text] [Related]
34. Mechanism of potentiation of tissue-type plasminogen activator. Lazos SA; Wong SS Biochem Mol Biol Int; 1995 Dec; 37(6):1071-77. PubMed ID: 8747537 [TBL] [Abstract][Full Text] [Related]
35. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. Bringmann P; Gruber D; Liese A; Toschi L; Krätzchmar J; Schleuning WD; Donner P J Biol Chem; 1995 Oct; 270(43):25596-603. PubMed ID: 7592732 [TBL] [Abstract][Full Text] [Related]
36. Making tissue-type plasminogen activator more fibrin specific. Paoni NF; Chow AM; Peña LC; Keyt BA; Zoller MJ; Bennett WF Protein Eng; 1993 Jul; 6(5):529-34. PubMed ID: 8415579 [TBL] [Abstract][Full Text] [Related]
37. Trinitrobenzoylated poly(D-lysine) as a stimulator of interactions between plasminogen, plasmin, and tissue-type plasminogen activator. Petersen LC; Suenson E Biochim Biophys Acta; 1986 Sep; 883(2):313-25. PubMed ID: 2943320 [TBL] [Abstract][Full Text] [Related]
38. [Plasminogen activation by a tissue activator and effector properties of fibrinogen-N-terminal disulfide (N-DSK) fibrin complex]. Makogonenko EM; Druzhina NN; Lugovskoĭ EV; Kolesnik LA; Kudinov SA Ukr Biokhim Zh (1978); 1991; 63(3):17-23. PubMed ID: 1926582 [TBL] [Abstract][Full Text] [Related]
39. Artificial exon shuffling between tissue-type plasminogen activator (t-PA) and urokinase (u-PA): a comparative study on the fibrinolytic properties of t-PA/u-PA hybrid proteins. de Vries C; Veerman H; Blasi F; Pannekoek H Biochemistry; 1988 Apr; 27(7):2565-72. PubMed ID: 3132969 [TBL] [Abstract][Full Text] [Related]
40. Regulation of plasminogen activation by components of the extracellular matrix. Stack S; Gonzalez-Gronow M; Pizzo SV Biochemistry; 1990 May; 29(20):4966-70. PubMed ID: 2114170 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]